Latest Ratios: P/E Ratio -11.7x · EV/EBITDA N/A · ROE N/A. (2000–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $199M | $266M | $80M | $100M | $67M | $121M | $128M | $149M | $135M | $119M | $29M |
| Enterprise Value | $315M | $382M | $172M | $146M | $88M | $111M | $101M | $102M | $127M | $116M | $13M |
| P/E Ratio → | -11.67 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | — | — | — | — | — | 46.31 | 5.28 | 3.28 | 19.60 | 99.45 | 2.38 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | -227.7% | -67.2% | -50.7% | -343.6% | -245.8% | -115.7% |
| ROA | -166.6% | -166.6% | -205.9% | -166.0% | -122.9% | -85.5% | -60.1% | -46.3% | -211.1% | -162.7% | -101.6% |
| ROIC | — | — | — | — | — | — | — | — | — | — | — |
| ROCE | -174.6% | -174.6% | — | -366.1% | -186.8% | -105.9% | -67.1% | -51.1% | -336.2% | -246.0% | -115.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | 11.11 | 0.00 | 0.00 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | — | -4.05 | -1.12 | -1.04 | -1.20 | -2.56 | -1.28 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -3.21 | -3.21 | -7.49 | -13.71 | -36.54 | -61.43 | -268.71 | -151.80 | -40.37 | -1352.92 | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.42 | 2.42 | 0.49 | 1.77 | 1.58 | 4.63 | 5.46 | 17.10 | 4.19 | 1.29 | 4.18 |
| Quick Ratio | 2.42 | 2.42 | 0.49 | 1.77 | 1.58 | 4.63 | 5.46 | 17.10 | 4.19 | 1.29 | 4.18 |
| Cash Ratio | 2.21 | 2.21 | 0.43 | 1.64 | 1.43 | 4.39 | 5.03 | 16.84 | 3.92 | 1.03 | 4.06 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | 0.1% | — | — | 0.1% | 0.1% | 0.3% | 0.7% | 1.0% | 2.6% |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.1% | 0.1% | 0.3% | 0.7% | 1.0% | 2.6% |
| Shares Outstanding | — | $64M | $62M | $60M | $59M | $59M | $57M | $52M | $39M | $36M | $29M |
Includes 30+ ratios · 26 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying GALT stock.
Galectin Therapeutics Inc.'s current P/E ratio is -11.7x. This places it at the 50th percentile of its historical range.
Based on historical data, Galectin Therapeutics Inc. is trading at a P/E of -11.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Key Metrics
Top Statement Risk
Debt overhang versus vanishing liquidity
Metrics are mathematically derived from official filings.
Current Ratio Collapse Flags Immediate Strain
GALT's current ratio plunged from 2.15 in 2026Q1 to 0.10 in 2026Q2, per its quarterly balance sheets, implying near-term obligations exceed liquid assets roughly tenfold and marking the weakest liquidity reading in the ten-quarter series.
The 0.10 current and quick ratios in 2026Q2 are identical, which indicates the entire current asset base is effectively cash-like — consistent with the $13.3M cash position against $151.7M in total liabilities reported elsewhere in the balance sheet. The swing from 2.15 to 0.10 within a single quarter suggests either a large current-maturity reclassification of the $137.7M debt load or an abrupt settlement of current obligations; either way, the buffer against a missed payment or covenant event appears negligible, and investors should monitor the maturity schedule disclosed in the notes for near-term refinancing dependence. Under stress, this profile implies the company would likely need an immediate financing event to meet obligations maturing within twelve months, though the exact timing cannot be confirmed from ratio data alone.
Coverage Improving From a Meaningless Base
Interest coverage improved from -9.92 in 2024Q1 to -0.41 in 2026Q2, according to Galectin's reported results, a trend driven entirely by the R&D-driven contraction in operating losses rather than any expansion in earnings available to service debt.
The arithmetic improvement in coverage mirrors the 68% reduction in quarterly operating losses noted in prior income statement analysis — when losses shrink, the denominator shrinks toward zero, mechanically lifting a negative coverage ratio without adding any real debt-service capacity. With $137.7M in total debt against $14.8M in total assets and a negative $136.9M equity position, the relevant question is not coverage but repayment source: no operating cash flow exists to amortize principal, so the structure appears dependent on refinancing, conversion, or negotiated extension. The D/E ratio is unavailable in this dataset, but the 9.3x debt-to-asset figure from the balance sheet analysis frames the true leverage far more meaningfully than any book-based ratio could.
Zero Revenue Leaves Margins Undefined
GALT's ROA has run between -28.6% and -71.3% over ten quarters through 2026Q2, per reported financial statements, reflecting pure cash burn against a shrinking asset base rather than operating underperformance, since gross, operating, and net margins remain undefined absent any revenue.
The ROA volatility — from -71.3% in 2025Q1 to -28.6% in 2026Q1 before reverting to -59.9% in 2026Q2 — tracks the sequential R&D spending cuts documented in the income statement analysis rather than any shift in earning power; the -59.9% reading likely reflects the $9.1M net loss in 2026Q2, which exceeded the $4.0M operating loss by $5.1M of below-the-line items. Because no margin metric is computable, profitability here is effectively a function of burn rate alone, and the apparent improvement in losses is a cost-retrenchment story, not a margin-expansion story. Analysts should treat the net-loss-to-operating-loss gap as the key quality-of-earnings flag, since it suggests non-operating volatility that could recur regardless of the trimmed R&D budget.
Asset Turnover Unavailable, Working Capital Signals Mixed
Asset turnover, DSO, DIO, DPO, and the cash conversion cycle are all unavailable for GALT across the ten-quarter window through 2026Q2, per its reported ratio disclosures, reflecting a business with no inventory, receivables, or payables scale sufficient to generate meaningful turnover metrics.
Working capital nevertheless contributed $6.6M of cumulative cash over the period per the cash flow statements, with 2026Q2 adding $2.5M — a favorable swing that partially offsets the operating burn but appears too small relative to the $151.7M liability stack to change the runway math materially. With zero capex across all ten quarters, the traditional cash conversion cycle framework offers no analytical traction; the relevant efficiency question for GALT is burn-per-quarter against undisclosed cash balances, not days-sales-outstanding dynamics. Given the 0.10 current ratio in 2026Q2, any working capital contribution in future quarters would more likely reflect deferral of payables than genuine operational efficiency, warranting scrutiny of accrual movements in upcoming filings.
Peer Set Highlights Structural Distinction
Against peers like MDGL (-56.6% ROE) and CRNX (-44.2% ROE), GALT's ROE is unavailable per reported data, yet its -59.6% ROA in 2026Q2 and zero-revenue profile place it at the extreme end of a pre-commercial cohort already pricing pipeline optionality.
Where MDGL and CRNX at least carry commercial-stage or late-stage pipelines supporting $10.2B and $9.0B valuations, GALT's reported figures show no revenue in ten quarters alongside a $137.7M debt load that peers of its scale do not carry — CRNX's 0.05 D/E and ELVN's 0.00 D/E underscore how unusual this capital structure is for a pre-revenue biotech. Halozyme's 50.2x P/E and 19.1x EV/EBITDA demonstrate what commercial success looks like in the sector, but those multiples are inapplicable to GALT given its undefined EV/EBITDA and P/S. The structural question for GALT versus this group is not whether margins lag, but whether the debt overhang — unique among the peer set shown — has already impaired equity recovery potential relative to unencumbered peers.
Debt-to-Equity Is the Misapplied Ratio Here
D/E, unavailable for GALT per reported disclosures, is the ratio most commonly misapplied to distressed biotechs, and its book-based construction would understate GALT's true economic leverage given the negative $136.9M equity base rendering any D/E figure either meaningless or infinite.
With shareholders' equity already negative $136.9M against $137.7M of debt and $446.8M in accumulated deficits, conventional leverage ratios collapse into arithmetic noise, while the 9.3x debt-to-asset ratio and the 0.10 current ratio from 2026Q2 convey the solvency picture far more honestly. The more useful diagnostic is the interplay between the quarterly burn (narrowed to roughly $2.4M per the FCF analysis) and the undisclosed cash balance versus the debt maturity profile — a relationship no single standard ratio captures. Additionally, if the convertible notes carry embedded derivative liabilities or anti-dilution features not itemized in summary data, as the prior balance sheet analysis flags, reported debt itself may understate the claim on future equity value, meaning investors should anchor on convertible terms disclosed in the notes rather than on any headline leverage multiple.